Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Exp Toxicol Pathol. 2008 Sep 6;61(1):1–12. doi: 10.1016/j.etp.2008.06.008

Figure 2. Rat liver lesions.

Figure 2

Figure 2

Figures A and B: Hepatocytic hypertrophy grade 3 in a male rat treated for 3 months by gavage with 500 mg/kg of DE-71. A - X12.5; B - X50. Compare with control animal, Figure I and J, respectively. H&E.

Figures C and D: Hepatocytic hypertrophy grade 4 in a male rat treated for 3 months by gavage with 500 mg/kg of DE-71. C - X12.5; D - X50. Note the presence of hepatocytic fatty degeneration (black arrows), and single hepatocytic necrosis (blue arrow). Compare with control animal, Figure I and J, respectively. H&E.

Figures E and F: Hepatocytic hypertrophy grade 3 in a male rat treated for 3 months by gavage with 100 mg/kg of DE-71. E - X12.5; F - X50. Note the presence of hepatocytic fatty degeneration (black arrows), and single hepatocytic necrosis (blue arrow). Compare with control animal, Figure I and J, respectively. H&E.

Figures G and H: Hepatocytic hypertrophy grade 3 in a male rat treated for 3 months by gavage with 50 mg/kg of DE-71. G - X12.5; H - X50. Note the presence of hepatocytic fatty degeneration (black arrows). Compare with control animal, Figure I and J, respectively. H&E.

Figures I and J: The morphological aspect of hepatocytes from a control male rat from the DE-71 study. X 12.5; B - X50. H&E.